Literature DB >> 9121755

Human autologous serum for the treatment of full-thickness macular holes. A preliminary study.

P E Liggett1, D S Skolik, B Horio, Y Saito, V Alfaro, W Mieler.   

Abstract

BACKGROUND: Recent studies have shown the usefulness of pars plana vitrectomy with/or without the use of transforming growth factor-beta in treating macular holes. The purpose of the present study is to test the efficacy of autologous serum in conjunction with current surgical techniques in the repair of stage 3 or 4 macular holes.
METHODS: A total of 11 eyes in nine patients with stage 3 or 4 full-thickness macular holes were treated. The patients ranged in age from 53 to 80 years (mean, 68 years). These patients were followed for 4 to 11 months (mean, 8.4 months). Preoperative best-corrected visual acuity ranged from 2/200 to 20/80 (mean, 20/200). A standardized pars plana vitrectomy was performed with removal of the posterior hyaloid and/or removal of epiretinal membranes, fluid-gas exchange. Autologous serum (0.1 ml) was instilled over the macular hole followed by perfluorocarbon gas tamponade and head positioning for 2 weeks.
RESULTS: All 11 (100%) of the eyes in 9 patients had resolution of the surrounding subretinal fluid and flattening of the macular hole. All of the eyes showed an improvement of at least two lines or more (mean, 4.7 lines) in visual acuity. Three eyes (27%) had visual acuities of 20/40 or better, and seven (64%) had visual acuities of 20/60 or better. No exuberant fibrosis proliferation was noted in any eye.
CONCLUSION: The results of this preliminary study indicate the possible benefit of autologous serum when used in conjunction with current surgical techniques in treating stage 3 or 4 macular holes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9121755     DOI: 10.1016/s0161-6420(95)30909-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment.

Authors:  H Hoerauf; H Klüter; E Joachimmeyer; J Roider; C Framme; P Schlenke; H Kirchner; H Lagua
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Peripheral visual field loss after vitreous surgery for macular holes.

Authors:  S Bopp; K Lucke; U Hille
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

3.  Retreatment of full-thickness macular hole: predictive value of optical coherence tomography.

Authors:  Jost Hillenkamp; Jürgen Kraus; Carsten Framme; Timothy L Jackson; Johann Roider; Veit-Peter Gabel; Helmut G Sachs
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

4.  Fundus autofluorescence in patients with macular holes imaged with a laser scanning ophthalmoscope.

Authors:  A von Rückmann; F W Fitzke; Z J Gregor
Journal:  Br J Ophthalmol       Date:  1998-04       Impact factor: 4.638

5.  Indocyanine green assisted retinal internal limiting membrane removal in stage 3 or 4 macular hole surgery.

Authors:  A K H Kwok; T Y Y Lai; W Man-Chan; D C F Woo
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

6.  The effect of autologous serum on vitrectomy with internal limiting membrane peeling for idiopathic macular hole.

Authors:  Ya-Hsin Kung; Tsung-Tien Wu
Journal:  J Ocul Pharmacol Ther       Date:  2013-01-16       Impact factor: 2.671

7.  Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2.

Authors:  M Minihan; M Goggin; P E Cleary
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

8.  Phacovitrectomy without prone posture for full thickness macular holes.

Authors:  P R Simcock; S Scalia
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

9.  Effects of mesenchymal stem cells and their exosomes on the healing of large and refractory macular holes.

Authors:  Xiaomin Zhang; Juping Liu; Bo Yu; Feifei Ma; Xinjun Ren; Xiaorong Li
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-30       Impact factor: 3.117

10.  Management of Stage IV Macular Holes: When Standard Surgery Fails.

Authors:  R Reis; N Ferreira; A Meireles
Journal:  Case Rep Ophthalmol       Date:  2012-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.